SCHEMBL3308238

SCHEMBL3308238

CC1CCN(C(=O)c2ccc3[nH]c4c(c3c2)CNCC4)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.66
CNR2 P34972 1/20 0.62
KMT2A Q03164 4/20 0.53
MAPT P10636 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
MEN1 O00255 2/20 0.53
HTT P42858 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
TP53 P04637 1/20 0.48
LMNA P02545 3/20 0.48
POLB P06746 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PARP1 P09874 1/20 0.46
RAD52 P43351 1/20 0.46
SIRT2 Q8IXJ6 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13329249 0.83 CNR1 (0.74) CNR1CNR2KMT2AMAPTSMN1; SMN2
SCHEMBL3311717 0.82 CNR1 (0.73) CNR1CNR2KMT2AMAPTSMN1; SMN2
SCHEMBL3310252 0.82 CNR1 (0.73) CNR1CNR2KMT2AMAPTSMN1; SMN2
SCHEMBL2019751 0.79 CNR1 (0.67) CNR1CNR2KMT2AMAPTSMN1; SMN2
SCHEMBL3305857 0.79 CNR1 (1.00) CNR1CNR2PARP1
SCHEMBL3308956 0.77 CNR1 (0.64) CNR1CNR2NPC1RAB9AALDH1A1
SCHEMBL13320191 0.77 MAPT (0.61) KMT2AMAPTSMN1; SMN2MEN1NPC1
SCHEMBL3312265 0.77 CNR1 (0.66) CNR1CNR2KMT2AMAPTSMN1; SMN2
SCHEMBL3310376 0.77 CNR1 (0.84) CNR1CNR2
SCHEMBL13360750 0.76 CNR1 (0.65) CNR1CNR2KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113502-A1 Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands ASTRAZENECA AB (SE) 2010-05-06 US disclosed
US-20100113502-A1 Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands ASTRAZENECA AB (SE) 2010-05-06 US disclosed
US-20100113502-A1 Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands ASTRAZENECA AB (SE) 2010-05-06 US disclosed
EP-1863810-A1 NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1' RECEPTOR LIGANDS AstraZeneca AB (SE) 2007-12-12 EP disclosed
WO-2006101434-A1 NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113502-A1 Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands CNR1, CNR2, OPRL1 CNR1 1/4885CNR2 2/4885KMT2A 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.